From this core mechanism Fc engineering has evolved over time into the "engine" of therapeutic antibody development. It ...
In a Phase II trial, LEVI-04 demonstrated a significant, dose-dependent reduction in bone marrow lesions (BML) compared with placebo in patients ...
Common cholesterol-lowering drugs may reduce risk of developing dementia: StudyLower cholesterol levels may play a key role ...
Early broadly neutralising antibody responses against the E1E2 glycoprotein seem to be important for preventing persistence ...
FOCUS is a randomized, double-blind, placebo-controlled crossover pilot study evaluating Tonix’s investigational intranasal potentiated oxytocin ...
FOCUS is a randomized, double-blind, placebo-controlled crossover pilot study evaluating Tonix's investigational intranasal potentiated oxytocin products in patients with Arginine-Vasopressin Deficien ...
Eli Lilly and Company today announced results from the primary overall survival (OS) analysis of the Phase 3 monarchE trial showing that two years of adjuvant Verzenio plus endocrine therapy (ET) ...
Researchers have discovered how unstructured segments of surface proteins regulate the biological function of a cell. Their study, published in Nature Communications, sheds new light on the interplay ...
EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating ...
Follicle-stimulating hormone (FSH), a glycoprotein secreted by gonadotroph cells of the anterior pituitary, is classically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback